Dexmedetomidine: 3 agencies, 2012–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused dexmedetomidine: all 9 decisive outcomes across 3 agencies were positive or positive with restrictions.
Assessment has run over 9.4 years, from 11 Jun 2012 at SMC (Scotland) to 17 Nov 2021 at HAS (France).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for dexmedetomidine at all.
Not every gap is a refusal: for dexmedetomidine, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
Against its own class, dexmedetomidine is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class N05C average 71%.
4 distinct indication wordings are recorded for dexmedetomidine by the agencies that label one in English (AWMSG and SMC).
The systems moved almost together: all 3 agencies opened a file on dexmedetomidine within a year of one another, starting with SMC (Scotland) on 11 Jun 2012.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
3 of the 3 agencies here assessed dexmedetomidine more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed dexmedetomidine.
The full ledger for dexmedetomidine reads 9 recommended, 2 not assessed and 1 non-submission.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 17 Nov 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 22 Apr 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 20 Mar 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 11 Feb 2019 | Sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation. | not recommended | source |
| AWMSG (Wales) | 8 Nov 2018 | Sedation of adult Intensive Care Unit patients requiring sedation level not deeper than arousal in response to verbal st… | outside AWMSG criteria | source |
7 further decisions for dexmedetomidine, across 3 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- melatonin — same ATC class N05C — Psycholeptics
- midazolam — same ATC class N05C — Psycholeptics
- daridorexant — same ATC class N05C — Psycholeptics
- remimazolam — same ATC class N05C — Psycholeptics
- zolpidem — same ATC class N05C — Psycholeptics
- tocilizumab — also decided by HAS in 2021Q4
Coverage: 12 decisions for dexmedetomidine from 3 agencies, 2012 to 2021. Data to 7 Sep 2026. ATC class N05C — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.